The United Kingdom and the United States have established a key bilateral deal that will preserve no duties on British drug shipments being sold in the US market.
Agreement Details of the Pact
As part of the deal, the UK has committed to raise spending on pharmaceuticals through the National Health Service (NHS). This move secures that duties on these crucial products will stay at zero for a period of 36 months.
This agreement is in response to previous warnings to hike import taxes on patented pharmaceutical products, with figures mentioned reaching 100%.
"This deal with the Britain bolsters the worldwide climate for new treatments and establishes long-overdue equity to U.S.–U.K. medicine commerce," an announcement said.
Economic Importance
Pharmaceuticals represent one of the Britain's biggest exports to the America, which is easily the largest destination for large UK drugmakers.
Statistics show that in the one-year period to the end of the third quarter, the UK shipped medicines totaling £11.1bn to the US. This value represented 17.4% of British export trade in that span.
"This agreement secures work, stimulates capital expenditure and paves the way for the UK to emerge as a worldwide center for life sciences," a government official stated.
Detailed British Pledges
The agreement entails several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it considers new therapies to be too expensive by a quarter.
- Boosted Medicine Funding: There is a target to increase total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage drug companies must pay back to the NHS to control costs will be restricted at 15%. Last year, refunds were more than twenty percent.
Broader Context
The deal comes amid a long-running row between the pharmaceutical industry and the ministers over drug pricing and approval rates.
The disagreement were heightened by claims that US patients were paying a premium for the same drugs than patients in the Britain and the EU.
In recent months, several major drug company projects in the UK have been halted or cancelled, while major investments have been announced toward US facilities.
One official publicly accepted that the NHS needed to spend more on treatments, noting that its expenditure on drugs had decreased as a percentage of its resources over the previous ten-year period.
